Imiglucerase is a man-made form of the naturally-occurring protein beta-glucocerebrosidase. A deficiency of beta-glucocerebrosidase is called Gaucher disease. Imiglucerase is used for the treatment of Type 1 Gaucher disease that results in one or more of the following: anemia (low level of red blood cells), thrombocytopenia (low level of platelets), bone disease, hepatomegaly (enlargement of the liver), or splenomegaly (enlargement of the spleen). Imiglucerase may also be used for purposes other than those listed here.
Cerezyme is a product that is produced by recombinant DNA technology using the mammalian culture of the cell. Cerezyme is supplied as a sterile, non-pyrogenic, and can be a white or off white lyophilized product. It is offered as treatment for Gaucher disease, which causes anemia, enlargement of the spleen and liver and bone disease.